Dapagliflozin plus methylcobalamin improved nerve function and glucose control in diabetic neuropathy.

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

The Subject Expert Committee (SEC) for Endocrinology & Metabolism under the Central Drugs Standard Control Organisation ...

FRIDAY, June 6, 2025 (HealthDay News) -- For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for improvement of MASH without ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

Dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in a randomized trial in China. The study included younger patients who were predominantly ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney ...

People with type 1 diabetes require insulin therapy for life, but the side effects can include weight gain and chronic kidney ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

In last two decades, the country’s IP model continues to serve as a global benchmark for balancing innovation with public ...